Magazine Article | January 4, 2021

How A First-Time Pharma CEO Faces Hypergrowth

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

“BUY WHAT YOU KNOW.”

It’s a saying meant to guide investors. The notion is, if you are going to invest in a company stock, you should know and understand what it is that company does. That same principle could be applied to how one manages their career. For example, Jeffrey Nau, Ph.D., knows the human eye — very well. “I’ve been involved in ophthalmic drug development my entire career,” he says. So, it’s probably no surprise that he’d one day become president and CEO of a clinical-stage company focused on discovery, development, and commercialization of therapies to treat the eye. What’s odd, though, is that the key asset his company, Oyster Point Pharma, is developing is a nasal spray for the eye. Specifically, OC-01 (varenicline) is being developed to treat dry eye disease (DED) and neurotrophic keratitis, which is a degenerative eye disease characterized by decreased corneal sensitivity and poor corneal healing.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: